25-NSE - Redwoods Acquisition Corp. (0001907223) (Subject)

425 - Redwoods Acquisition Corp. (0001907223) (Subject)

8-K - Redwoods Acquisition Corp. (0001907223) (Filer)

425 - Redwoods Acquisition Corp. (0001907223) (Subject)

8-K/A - Redwoods Acquisition Corp. (0001907223) (Filer)

425 - Redwoods Acquisition Corp. (0001907223) (Subject)

8-K - Redwoods Acquisition Corp. (0001907223) (Filer)

10-Q - Redwoods Acquisition Corp. (0001907223) (Filer)

NT 10-Q - Redwoods Acquisition Corp. (0001907223) (Filer)

425 - Redwoods Acquisition Corp. (0001907223) (Subject)

NEW YORK, June 24, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or the "Company") announces the Company's common shares and warrants will begin trading on the NASDAQ Global Market under the ticker symbols "WENA" and "WENAW", respectively. ANEW is a specialty pharmaceutical company specializing in the advancement of diagnostics and novel disease-modifying therapies for neurological and age-related disorders. Dr. Joseph Sinkule, Founder and CEO of ANEW, commented, "Today marks our first day as a publicly traded company and as a dedicated leader in the development of novel disease-modifying therapies for neurological and age-related disorders. We're a relatively new company but our manageme

ANEW MEDICAL, INC.'s shares and warrants are expected to begin trading on the Nasdaq Global Market under the tickers "WENA" and "WENAW", respectively.  NEW YORK, NY, June 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company"), a biopharmaceutical technology company focused on developing disruptive new therapies to treat the central nervous system ("CNS") and neurodegenerative diseases, and Redwoods Acquisition Corp. (NASDAQ: RWOD) ("RWOD"), a publicly-traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"). The combined company will be named "ANEW MEDICAL, INC." a

NEW YORK, March 4, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases. This intellectual property was licensed by ANEW from UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) and INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) in Barcelona, Spain on an exclusive worldwide basis and ANEW paid

ANEW MEDICAL is developing a platform and commercializing novel gene therapies to alleviate and/or reverse the progression of neurodegenerative diseases.ANEW MEDICAL intends to use the proceeds from the merger transaction to progress its lead gene therapy programs including for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).NEW YORK, June 6, 2023 /PRNewswire/ -- ANEW MEDICAL, INC. (OTC:LEAS), an early-stage biotechnology company focused on developing disruptive new therapies to treat age-related neurodegenerative diseases, previously announced that it has entered into a definitive business combination agreement with Redwoods Acquisition Corp. (NASDAQ:RWOD, ", Redwoods", )))

NEW YORK, May 31, 2023 /PRNewswire/ -- Redwoods Acquisition Corp. (the "Company") (NASDAQ:RWOD) today announced that it received a delinquency notification letter ("Notice") from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") on May 24, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the "Form 10-Q"). The Listing Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Company filed

ANEW MEDICAL, INC. ("ANEW") has entered into a definitive business combination agreement with Redwoods Acquisition Corp. (NASDAQ:RWOD).ANEW is developing a platform and commercializing novel gene therapies to alleviate and/or reverse the progression of neurogenerative diseases.ANEW intends to use the proceeds from the transaction to progress its lead gene therapy programs including for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).NEW YORK, May 30, 2023 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or the "Company"), an early-stage biotechnology company focused on developing disruptive new therapies to treat neurodegenerative diseases, announced today that it has entered into

SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)

SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)

SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)

SC 13G - Redwoods Acquisition Corp. (0001907223) (Subject)

SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)

SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)